Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear?
- 16 February 2010
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 152 (4) , 211-217
Abstract
Some postmenopausal women who receive hormone replacement therapy have an increased risk for coronary heart disease (CHD). These data from the Women's Health Initiative trial examine how the timing... Background: Estrogen plus progestin therapy increases the risk for coronary heart disease (CHD) in postmenopausal women. However, this increased risk might be limited to the first years of use and ...Keywords
This publication has 28 references indexed in Scilit:
- Causal Inference from Longitudinal Studies with Baseline RandomizationThe International Journal of Biostatistics, 2008
- Menopausal Symptoms and Treatment-Related Effects of Estrogen and Progestin in the Womenʼs Health InitiativeObstetrics & Gynecology, 2005
- Executive SummaryObstetrics & Gynecology, 2004
- Evaluation of Cardiovascular Event Rates With Hormone Therapy in Healthy, Early Postmenopausal WomenArchives of internal medicine (1960), 2004
- Estrogen plus Progestin and the Risk of Coronary Heart DiseaseNew England Journal of Medicine, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive MenEpidemiology, 2000
- Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990–1995Journal of General Internal Medicine, 2000
- Design of the Women’s Health Initiative Clinical Trial and Observational StudyControlled Clinical Trials, 1998
- TREATMENT OF GROUPED OBSERVATIONS IN LIFE STUDIES1977